Journal of Internal Medicine 1994; **236**: 695–699

Author Index

Abad MA *see* Andreu *et al.*
Abboud L, Hir J, Eisen I, Markiewicz W. The influence of thrombolytic therapy on the predictive value of exercise testing 3 weeks after acute myocardial infarction, 537
Abs R, Raes D, Vercruysse H. Association of isolated hypogonadotrophic hypogonadism, pronounced hypodontia and the Wolff–Parkinson–White syndrome, 349
Adubofour KOM *see* Nyarko NK *et al.*
Agewall S, Wikstrand J, Samuelsson O, Persson B, Andersson OK, Fagerberg B, on behalf of the Risk Factor Intervention Study Group. The efficacy of multiple risk factor intervention in treated hypertensive men during long-term follow-up, 651
Aledort LM, Haschmeyer RH, Pettersson H, the Orthopaedic Outcome Study Group. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs, 391
Alvarsson M, Efendic S, Grill VE. Insulin responses to glucose in healthy males are associated with adult height but not with birth weight, 275
Andersen LB. Blood pressure, physical fitness and physical activity in 17-year-old Danish adolescents, 323
Andersson A *see* Brattström *et al.*
Andersson C, Lithner F. Hypertension and renal disease in patients with acute intermittent porphyria, 169
Andersson OK *see* Agewall *et al.*
Andreu J
Abad MA, Sanchez-Quijano A, Torronteras R, Luque F, Garcia de las Heras J, Soto B, Pineda JA, Leal M, Lissen E. High rate of nonspecific anti-hepatitis C reactivity amongst homosexual men, in comparison with that found in other sexually active groups and blood donors, 73
see also Soto *et al.*
Arber N *see* Rattan *et al.*
Arenas JI *see* Soto *et al.*
Arisato T *see* Matsumuro *et al.*
Arkkila PET, Kantola IM, Viikari JS. Limited joint mobility in type 1 diabetic patients: correlation to other diabetic complications, 215
Armellini F *see* Zamboni *et al.*
Arnesen H *see* Hurlen *et al.*
Asplund R. Sleep and cardiac diseases amongst elderly people, 65
Asplund–Carlson A, Carlson LA. Studies in hypertriglyceridaemia. 1 Serum triglyceride distribution, 57
Aymard B *see* Hoen *et al.*

Baccarani M *see* Fanin *et al.*
Bacci G *see* Fabbri *et al.*
Bachmann F *see* Lifnen *et al.*; Verstraete *et al.*
Barbado FJ *see* Poveda *et al.*
Barnes RW *see* Berglund *et al.*
Baty V *see* Hoen *et al.*
Bell H, Skinningsrud A, Raknerud N, Try K. Serum ferritin and transferrin saturation in patients with chronic alcoholic and non-alcoholic liver diseases, 315
Berg K *see* Birkeland *et al.*
Bergamo Andreis I *see* Zamboni *et al.*
Berglund GL
Riley WA, Barnes RW, Furberg CD. Quality control in ultrasound studies on atherosclerosis, 581
Ultrasound in clinical trials of atherosclerosis, 549
Bergstrand L, Olsson AG, Erikson U, Holme I, Johansson J, Kaijser L, Lassvik C, Mölgaard J, Nilsson S, Stenport G, Walldius G. The relation of coronary and peripheral arterial disease to the severity of femoral atherosclerosis in hypercholesterolaemia, 367
Bergström R. The use and misuse of meta-analysis in clinical medicine, 3
Berne C *see* Lind *et al.*
Bianchi-Porro G *see* Montrone *et al.*
Birkeland KI, Hanssen KF, Urdal P, Berg K, Vaaler S. A long-term, randomized, comparative study of insulin versus sulfonylurea therapy in type 2 diabetes, 305
Bissoli L *see* Zamboni *et al.*
Bissuel F, Leport C, Perronne C, Longuet P, Vilde J-L. Fever of unknown origin in HIV-infected patients: a critical analysis of a retrospective series of 57 cases, 529
Bjorndal A *see* Midthjell *et al.*
Blychert E *see* Kjellström *et al.*
Boe J *see* Naalsund *et al.*
Bosello O *see* Zamboni *et al.*
Bots ML *see* Grobbee *et al.*
Brattström L, Lindgren A, Israelsson B, Andersson A, Hultberg B. Homocysteine and cysteine: determinants of plasma levels in middle-aged and elderly subjects, 633
Britton M *see* Rödén-Jüllig *et al.*
Brodin H *see* Stalfelt *et al.*
de Bruin TWA, Croon CDL, de Klerk JMH, van Isselt JW. Standardized radioiodine therapy in Graves' disease: the persistent effect of thyroid weight and radioiodine uptake on outcome, 507
Bruno CM *see* Neri *et al.*
Brusco G *see* Corazza *et al.*
Byington RP *see* Furberg *et al.*

Cagianelli MA *see* Ferri *et al.*
Camacho J *see* Poveda *et al.*
Canton P *see* Hoen *et al.*
Carlson LA *see* Asplund–Carlson
Carmeliet P, Mulligan RC, Collen D. Transgenic animals as tools for the study of fibrinolysis *in vivo*, 455
Caruso I *see* Montrone *et al.*
Cecchetti R *see* Ferri *et al.*
Christensen AH, Logan RPH, Noach LA, Gjorup T. Do clinicians accept the role of *Heliobacter pylori* in duodenal ulcer disease: a survey of European gastroenterologists and general practitioners, 501
Christensen L *see* Strauss *et al.*
Collen D

de Bono DP, Lijnen HR, Pannekoek H. Development of novel thrombolytic agents, 433
see also Carmeliet *et al.*; Lifnen HR *et al.*
Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy, 619
Corazza GR, Di Sario A, Sacco G, Zoli G, Treggiari EA, Brusco G, Gasbarrini G. Subclinical coeliac disease: an anthropometric assessment, 183
Cortes A *see* Soto *et al.*
Craven TE *see* Furberg *et al.*
Cristaldi R *see* Neri *et al.*
Croon CDL *see* de Bruin *et al.*

D'Amico R *see* Neri *et al.*
D'Angelo G *see* Neri *et al.*
Davidson JF *see* Verstraete *et al.*
Dayan D *see* Rattan *et al.*
de Bono DP *see* Collen *et al.*; van de Werf F *et al.*
Declerck PJ, Juhan-Vague I, Felez J, Wiman B. Pathophysiology of fibrinolysis, 425
Delgrange B *see* Delgrange E *et al.*
Delgrange E, Delgrange B, Wallon J, Rosoux P. Diagnostic approach to pulmonary lymphangioleiomyomatosis, 461
Després J-P, Lamarche B. Low-intensity exercise training, plasma lipoproteins and the risk of coronary heart disease, 7
Di Sario A *see* Corazza *et al.*
Duration of Anticoagulation (DURAC) Trial Study Group *see* Schulman S

Efendic S *see* Alvarsson *et al.*
Eisen I *see* Abboud *et al.*
Eiskjaer H, Nielsen CB, Pedersen EB. Pressure-dependent, enhanced natriuretic response to low-dose atrial natriuretic peptide infusion in essential hypertension, 665
Ellis V *see* Lifnen *et al.*
Elzouki A-NY
Eriksson S. Abdominal aortic aneurysms and alpha$_1$-antitrypsin deficiency, 587
Segelmark M, Wieslander J, Eriksson S. Strong link between the alpha$_1$-antitrypsin PIZ allele and Wegener's granulomatosis, 543
Emparanza JI *see* Soto *et al.*
van den Ende A *see* Knipscheer *et al.*
Erikson U *see* Bergstrand *et al.*
Eriksen J *see* Hurlen *et al.*
Eriksson S *see* Elzouki *et al.*; Janciauskiene *et al.*

Fabbri A, Motta E, Ferrari S, Longhi C, Marchi E, Bacci G, Figus E, Marchesini G. High-dose methotrexate treatment and liver function in patients with osteosarcoma, 209
Fagerberg B *see* Agewall *et al.*
Fagher B, Magnusson J, Thulin T. Direct and indirect blood pressure in normotensive and hypertensive subjects, 85
Fanin R, Baccarani M. Granulocyte-macrophage colony stimulating factor in acute non-lymphocytic leukaemia, 487
Felez J *see* Declerck *et al.*
Fernández-Calvet L, García-Mayor RVG. Incidence of pheochromocytoma in South Galicia, Spain, 675
Ferrari S *see* Fabbri *et al.*
Ferri C, Longombardo G, La Civita L, Greco F, Lombardini F, Cecchetti R, Cagianelli MA, Marchi S, Monti M, Zignego AL, Manns MP. Hepatitis C virus chronic infection as a common cause of mixed cryoglobulinaemia and autoimmune liver disease, 31
Figus E *see* Fabbri *et al.*
Foadi M *see* Savage *et al.*
Foliguet B *see* Hoen *et al.*
Frithz G *see* Pettersson *et al.*
Fugl-Meyer A *see* Rödén-Jüllig *et al.*
Furberg CD
Byington RP, Craven TE. Lessons learned from clinical trials with ultrasound end-points, 575
see also Berglund *et al.*

Gamst ON *see* Talstad *et al.*
Garcia de las Heras J *see* Andreu *et al.*
Garcia-Bengoechea M *see* Soto *et al.*
García-Mayor RVG *see* Fernández-Calvet *et al.*
Gasbarrini G *see* Corazza *et al.*
Giménez A *see* Poveda *et al.*
Gjorup T *see* Christensen *et al.*
Glaser B *see* Leibowitz *et al.*
González-García J *see* Poveda *et al.*
Gorsky M *see* Rattan *et al.*
Gotsche PC. Steroids and peptic ulcer:an end to the controversy?, 599
Grant A *see* Savage *et al.*
Graudal N *see* Milman *et al.*
Greco F *see* Ferri *et al.*
Grill VE *see* Alvarsson *et al.*
Grobbee DE, Bots ML. Carotid artery intima-media thickness as an indicator of generalized atherosclerosis, 567
Grode G *see* Milman *et al.*
Gustafsson C *see* Rödén-Jüllig *et al.*

Hagstrup Christensen J *see* Lambert-Jensen *et al.*
Hallengren B *see* Jönsson *et al.*; Papadopoulos *et al.*
van Halteren H. *see* Mathus-Vliegen *et al.*
Hanssen KF *see* Birkeland *et al.*
Haschmeyer RH *see* Aledort *et al.*
Haworth C *see* Savage *et al.*
Hedblad B, Ögren M, Janzon L, Isacsson S-O, Lindell SE. Low pulse-wave amplitude during reactive leg hyperaemia: an independent early marker for ischaemic heart disease and death. Results from the 21-year follow-up of the prospective cohort study 'Men born in 1914', Malmö, Sweden, 161
Heldal E *see* Naalsund *et al.*
Hir J *see* Abboud *et al.*
Hodis HN, Mack WJ. Risk factor assessment, treatment strategy and prevention of coronary artery disease: the need for a more rational approach, 111
Hoen B, Baty V, Aymard B, Judlin P, Foliguet B, Canton P. Giant-cell arteritis of the female genital tract, 345
Holme I *see* Bergstrand *et al.*
Holmen J *see* Midthjell *et al.*
Hörnblad Y *see* Papadopoulos *et al.*
Hosoi E *see* Yokoi *et al.*
Hultberg B *see* Brattström *et al.*
Hurlen M, Erikssen J, Smith P, Arnesen H, Rollag A. Comparison of bleeding complications of warfarin and warfarin plus acetylsalicylic acid: a study in 3166 outpatients, 299
Hyyppä MT *see* Pelttari *et al.*

Isacsson S-O *see* Hedblad *et al.*
Isaksson H
Östergren J. Prognosis in therapy-resistant hypertension, 643
see also Ludwigs *et al.*
Israelsson B *see* Brattström *et al.*
van Isselt JW *see* de Bruin *et al.*
Izumo S *see* Matsumuro *et al.*

Janciauskiene S, Eriksson S. An Interaction between gemfibrozil and alpha$_1$-antitrypsin, 357
Janzon L *see* Hedblad *et al.*
Jensen KH *see* Jorgensen *et al.*
Jess P. Personality pattern in peptic ulcer disease: a cohort study, 271
Joensuu T, Salonen R, Winblad I, Korpela H, Salonen JT. Determinants of fenoral and carotid artery atherosclerosis, 79
Johansen B *see* Naalsund *et al.*
Johansson J *see* Bergstrand *et al.*
Jönsson A, Hallengren B, Manhem P, Lilja B, Stavenow L, Ståhl E, Törnquist C. Cardiac pheochromocytoma, 93
Jørgensen T *see* Kay *et al.*
Judlin P *see* Hoen *et al.*
Juhan-Vague I *see* Declerck *et al.*

Kaijser L *see* Bergstrand *et al.*
Kantola I *see* Pelttari *et al.*
Kantola IM *see* Arkkila *et al.*
Karjalainen J *see* Niskanen *et al.*
Kastelein JJP *see* Knipscheer *et al.*
Kay L, Jørgensen T, Jensen KH. The epidemiology of irritable bowel syndrome in a random population: prevalence, incidence, natural history and risk factors, 23
Kjellström T, Blychert E, Lindgärde F. Short-term effects of felodipine in hypertensive type II diabetic males on sulfonylurea treatment, 51
de Klerk JMH *see* de Bruin *et al.*
Knipscheer HC, Nurmohamed MT, van den Ende A, Plaat B, Pruijs JW, Mulder WJ, Kastelein JJP. Gemfibrozil treatment of the high triglyceride–low high-density lipoprotein cholesterol trait in men with established atherosclerosis, 377
Kongerud B *see* Naalsund *et al.*
Korpela H *see* Joensuu *et al.*
Kristinsson JÖ, Valdimarsson Ö, Steingrimsdottir L, Sigurdsson G. Relation between calcium intake, grip strength and bone mineral density in the forearms of girls aged 13 and, 15, 385
Kronholm E *see* Pelttari *et al.*

La Civita L *see* Ferri *et al.*
Laakso M *see* Lehto *et al.*
Lamarche B *see* Després
Lambert-Jensen P, Mertz H, Nyvad O, Hagstrup Christensen J. Subacute cor pulmonale due to microscopic pulmonary tumour cell embolization, 597
Lassvik C *see* Bergstrand *et al.*
Leal M *see* Andreu *et al.*
Lehto S, Pyörälä K, Meittinen H, Rönnemaa T, Palomäki P, Tuomilehto J, Laakso M. Myocardial infarct size and mortality in patients with non-insulin-dependent diabetes mellitus, 291
Leibowitz G, Shapiro MS, Salameh M, Glaser B. Improvement of sleep apnoea due to acromegaly during short-term treatment with ocreotide, 231
Leport C *see* Bissuel *et al.*
Lifnen HR, Bachmann F, Collen D, Ellis V, Pannekoek H, Rijken DC, Thorsen S. Mechanisms of plasminogen activation, 415
Lijnen HR *see* Collen *et al.*
Lilja B *see* Jönsson *et al.*
Lind L, Berne C, Pollare T, Lithell H. Metabolic effects of isradipine as monotherapy or in combination with pindolol during long-term antihypertensive treatment, 37
Lindeberg S, Nilsson-Ehle P, Terént A, Vessby B, Scherstén B. Cardiovascular risk factors in a Melanesian population apparently free from stroke and ischaemic heart disease: the Kitava study, 331
Lindell SE *see* Hedblad *et al.*
Lindgärde F *see* Kjellström *et al.*
Lindgren A *see* Brattström *et al.*
Lindgren A, Olsson R. Liver reactions from trimethoprim, 281
Lissen E *see* Andreu *et al.*; Soto *et al.*
Lithell H *see* Lind *et al.*
Lithner F *see* Andersson
Logan RPH *see* Christensen *et al.*
Lombardini F *see* Ferri *et al.*
Longhi C *see* Fabbri *et al.*
Longombardo G *see* Ferri *et al.*
Longuet P *see* Bissuel *et al.*
Ludwigs U, Ruiz H, Isaksson H, Matell G. Factitious disorder presenting with acute cardiovascular symptoms, 685
Lundberg PO. Migraine therapy, 237
Luque F *see* Andreu *et al.*

Mack WJ *see* Hodis *et al.*
Magnusson J *see* Fagher *et al.*
Malinow MR. Homocyst(e)ine and arterial occlusive diseases, 603
Manhem P *see* Jönsson *et al.*
Manns MP *see* Ferri *et al.*
Mant MJ. Chronic idiopathic pure red cell aplasia: successful treatment during pregnancy and durable response to intravenous immunoglobulin, 593
Marchesini G *see* Fabbri *et al.*
Marchi E *see* Fabbri *et al.*
Marchi S *see* Ferri *et al.*
Markiewicz W *see* Abboud *et al.*
Maruyama I *see* Matsumuro *et al.*
Matell G *see* Ludwigs *et al.*
Mathus-Vliegen EMH, Van Halteren H, Tytgat GNJ. Malignant lymphoma in coeliac disease: various manifestations with distinct symptomatology and prognosis?, 43
Matsumuro K, Izumo S, Umehara F, Arisato T, Maruyama I, Yonezawa S, Shirahama H, Sato E, Osame M. Paraneoplastic vasculitic neuropathy: immunohistochemical studies on a biopsied nerve and post-mortem examination, 225
Meittinen H *see* Lehto *et al.*
Melchior TM, So»ensen H, Torp-Pedersen C. Hip and distal arm fracture rates in peri- and postmenopausal insulin-treated diabetic females, 203
Mertz H *see* Lambert-Jensen *et al.*
Midthjell K, Holmen J, Bjorndal A. Types of diabetes treatment in a total, Norwegian, adult population. The Nord-Trondelag Diabetes Study, 255

Milman N, Graudal N, Grode G, Munch E. No effect of high-dose, inhale steroids in pulmonary sarcoidosis: a double-blind, placebo-controlled study, 285
Mölgaard J *see* Bergstrand *et al.*
Monti M *see* Ferri *et al.*
Montrone F, Petrillo M, Caruso I, Bianchi-Porro G. A comparison of severe gastric damage as a result of pirprofen and naproxen treatment in rheumatoid arthritis: a controlled endoscopic study, 153
Moroni M *see* Porta *et al.*
Motta E *see* Fabbri *et al.*
Mulder WJ *see* Knipscheer *et al.*
Mulligan RC *see* Carmeliet *et al.*
Munch E *see* Milman *et al.*

Naalsund A, Heldal E, Johansen B, Kongerud B, Boe J. Deaths from pulmonary tuberculosis in a low-incidence country, 137
Nakanishi M *see* Yokoi *et al.*
Nastasi G *see* Porta *et al.*
Navascués CA *see* Soto *et al.*
Neri S, Bruno CM, Raciti C, D'Angelo G, D'Amico R, Cristaldi R. Alteration of oxide reductive and haemostatic factors in type 2 diabetics, 495
Nielsen CB *see* Eiskjaer *et al.*
Nilsson S *see* Bergstrand *et al.*
Nilsson-Ehle P *see* Lindeberg *et al.*
Niskanen L, Karjalainen J, Siitonen O, Uusitupa M. Metabolic evolution of type 2 diabetes: a 10-year follow-up from the time of diagnosis, 263
Noach LA *see* Christensen *et al.*
Nurmohamed MT *see* Knipscheer *et al.*
Nyarko NK, Adubofour KOM, Ofei F, Pobee JOM, Owusu SK. Serum lipids and lipoprotein in adult Ghanaians, 251
Nyvad O *see* Lambert-Jensen *et al.*

Ofei F *see* Nyarko *et al.*
Ögren M *see* Hedblad *et al.*
Olsson AG *see* Bergstrand *et al.*
Olsson R *see* Lindgren *et al.*
Orthopaedic Outcome Study Group *see* Aledort *et al.*
Osame M *see* Matsumuro *et al.*
Östergren J *see* Isaksson
Owusu SK *see* Nyarko *et al.*

Paget NS *see* Saunders *et al.*
Palomäki P *see* Lehto *et al.*
Pannekoek H *see* Collen *et al.*; Lifnen *et al.*
Papadopoulos KI, Hörnblad Y, Hallengren B. The occurrence of polyglandular autoimmune syndrome type III associated with coeliac disease in patients with sarcoidosis, 665
Pedersen EB *see* Eiskjaer *et al.*
Pelttari L, Rauhala E, Polo O, Hyyppä MT, Kronholm E, Viikari JS, Kantola I. Upper airway obstruction in hypothyroidism, 177
de Pergola G *see* Zamboni *et al.*
Perronne C *see* Bissuel *et al.*
Persson B *see* Agewall *et al.*
Peten EP, Striker LJ. Progression of glomerular diseases, 241
Petrillo M *see* Montrone *et al.*
Pettersson H *see* Aledort *et al.*
Pettersson L, Frithz G, Ronquist G. Direct effect of insulin on ^{45}calcium uptake in human erythrocytes, 197
Picazo ML *see* Poveda *et al.*
Pineda JA *see* Andreu *et al.*
Plaat B *see* Knipscheer *et al.*
Pobee JOM *see* Nyarko *et al.*
Pollare T *see* Lind *et al.*
Polo O *see* Pelttari *et al.*
Porkka KVK, Viikari JS. Should children or young adults be screened for serum lipid levels to prevent adult coronary heart disease? Experience from the Cardiovascular Risk in Young Finns Study, 115
Porta C, Moroni M, Nastasi G. Metachromatous occurrence of seminoma and Hodgkin's lymphoma in the same patient with late-onset colon cancer, 91
Poveda F, González-García J, Picazo ML, Giménez A, Camacho J, Barbado FJ, Vázquez-Rodríguez JJ. Systemic polyarteritis nodosa as the intial manifestation of a gastric adenocarcinoma, 679
Poynard T *see* Conn *et al.*
Probst M *see* Schüppel *et al.*
Pruijs JW *see* Knipscheer *et al.*
Pyörälä K *see* Lehto *et al.*

Raciti C *see* Neri *et al.*
Raes D *see* Abs *et al.*
Raknerud N *see* Bell *et al.*
Rattan J, Schneider M, Arber N, Gorsky M, Dayan D. Sucralfate suspension as a treatment of recurrent aphthous stomatitis, 341
Rauhala E *see* Pelttari *et al.*
Riestra S *see* Soto *et al.*
Rijken DC *see* Lifnen *et al.*
Riley WA *see* Berglund *et al.*
Risk Factor Intervention Study Group *see* Agewall *et al.*
Roberts LAG. Bone marrow transplantation in sickle cell anaemia, 483
Rödén-Jüllig A, Britton M, Gustafsson C, Fugl-Meyer A. Validation of four scales for the acute stage of stroke, 125
Rodrigo L *see* Soto *et al.*
Rodriguez M *see* Soto *et al.*
Rollag A *see* Hurlen *et al.*
Rönnemaa T *see* Lehto *et al.*
Ronquist G *see* Pettersson *et al.*
Rosoux P *see* Delgrange *et al.*
Ruiz H *see* Ludwigs *et al.*

Sacco G *see* Corazza *et al.*
Saito S *see* Yokoi *et al.*
Salameh M *see* Leibowitz *et al.*
Salonen JT
Salonen R. Risk factors for carotid and femoral atherosclerosis in hypercholesterolaemic men, 561
see also Joensuu *et al.*
Salonen R *see* Joensuu *et al.*; Salonen JT
Salonen R, *see also* Joensuu *et al.*
Samuelsson O *see* Agewall *et al.*
Sanchez-Quijano A *see* Andreu *et al.*; Soto *et al.*
Sato E *see* Matsumuro *et al.*
Saunders NA, Paget NS. Maintenance of professional standards and the recertification of physicians, 363
Savage D, Foadi M, Haworth C, Grant A. Marked eosinophilia in an immunosuppressed patient with strongyloidiasis, 473
Scherstén B *see* Lindeberg *et al.*
Schneider M *see* Rattan *et al.*

Schulman S, Duration of Anticoagulation (DURAC) Trial Study Group. Quality of oral anticoagulant control and treatment in Sweden, 143
Schüppel R, Probst M. Acute cholestatic hepatitis and the sudden rise of the pacing threshold 5 weeks after VVI-pacemaker implantation, 353
Segelmark M *see* Elzouki *et al.*
Shapiro MS *see* Leibowitz *et al.*
Shigekiyo T *see* Yokoi *et al.*
Shirahama H *see* Matsumuro *et al.*
Sigurdsson G *see* Kristinsson *et al.*
Siitonen O *see* Niskanen *et al.*
Skinningsrud A *see* Bell *et al.*
Smith P *see* Hurlen *et al.*
Sørensen H *see* Melchior *et al.*
Soto B *see* Andreu *et al.*
Soto E, Rodrigo L, Garcia M, Sanchez-Quilano A, Riestra S, Arenas JI, Andreu, Rodriguez, Emparanza JI, Torres Y, Navascués, Cortes A, Lissen E. Heterosexual transmission of HCV and possible role of coexistent HIV in the index case, . Multicentre study of 423 pairings., 515
Stahl E *see* Jönsson *et al.*
Stalfelt AM, Brodin H. Costs over time in conventional treatment of acute myeloid leukaemia. A study exploring changes in treatment strategies over two decades, 401
Stavenow L *see* Jönsson *et al.*
Stegmayr BG *see* Wirell *et al.*
Steingrimsdottir L *see* Kristinsson *et al.*
Stenport G *see* Bergstrand *et al.*
Strauss G, Christensen L, Zapf J. Tumour-induced hypoglycaemia due to 'big' IGF-II, 97
Striker LJ *see* Peten

Talstad I, Gamst ON. Warfarin resistance due to malabsorption, 465
Teisberg P. Disease caused by expanding genes, 1
Terént A *see* Lindeberg *et al.*
Thorsen S *see* Lifnen *et al.*
Thulin T *see* Fagher *et al.*
Todesco T *see* Zamboni *et al.*
Törnquist C *see* Jönsson *et al.*
Torp-Pedersen C *see* Melchior *et al.*
Torres Y *see* Soto *et al.*
Torronteras R *see* Andreu *et al.*
Treggiari EA *see* Corazza *et al.*
Try K *see* Bell *et al.*
Tuomilehto J *see* Lehto *et al.*
Turcato E *see* Zamboni *et al.*
Turpie AGG *see* Verstraete *et al.*
Tytgat GNJ *see* Mathus-Vliegen *et al.*

Umehara F *see* Matsumuro *et al.*
Umemoto K *see* Yokoi *et al.*
Urdal P *see* Birkeland *et al.*
Uusitupa M *see* Niskanen *et al.*

Vaaler S *see* Birkeland *et al.*
Valdimarsson Ö *see* Kristinsson *et al.*
Vázquez-Rodríguez JJ *see* Poveda *et al.*
Vercruysse H *see* Abs *et al.*
Verhaeghe R *see* Verstraete *et al.*
Verstraeta M. The role of the fibrinolytic system in the pathophysiology and treatment of thrombosis, 411
Verstraete M *see* van de Werf *et al.*
Verstraete M, Bachmann F, Davidson JF, Turpie AGG, Verhaeghe R. The present status of thrombolytic treatment in noncardiac disorders, 447
Vessby B *see* Lindeberg *et al.*
Viikari JS *see* Arkkila *et al.*; Pelttari L *et al.*; Porkka *et al.*
Vilde J-L *see* Bissuel *et al.*

Walldius G *see* Bergstrand *et al.*
Wallon J *see* Delgrange *et al.*
Wendelhag I *see* Wikstrand
van de Werf F, de Bono DP, Verstraete M. Thrombolytic treatment of acute myocardial infarction, 439
Wester PO *see* Wirell *et al.*
Wieslander J *see* Elzouki *et al.*
Wikstrand J *see* Agewall *et al.*
Wikstrand J, Wendelhag I. Methodological considerations of ultrasound investigation of intima-media thickness and lumen diameter, 555
Wiman B *see* Declerck *et al.*
Winblad I *see* Joensuu *et al.*
Wirell MP, Wester PO, Stegmayr BG. Nutritional dose of magnesium in hypertensive patients on beta blockers lowers systolic blood pressure: a double-blind, cross-over study, 189

Yokoi K, Hosoi E, Nakanishi M, Umemoto K, Shigekiyo T, Saito S. Familial occurrence of two patients with malignant rheumatoid arthritis, 469
Yonezawa S *see* Matsumuro *et al.*

Zamboni M, Armellini F, Turcato E, de Pergola G, Todesco T, Bissoli L, Bergamo Andreis I, Bosello O. Relationship between visceral fat, steroid hormones and insulin sensitivity in premenopausal obese women, 521
Zapf J *see* Strauss *et al.*
Zignego AL *see* Ferri *et al.*
Zoli G *see* Corazza *et al.*

Journal of Internal Medicine 1994; **236**: 701–704

Subject Index

Acromegaly
  octreotide, sleep apnoea, 231
Adolescents
  bone mineral density (BMD), calcium intake, 385
  physical fitness and BP, 323
Adoption of medical technology, 501
Adrenal antibodies
  coeliac disease and sarcoidosis, 661
AIDS
  lactic acidosis, 478
Alcoholic liver diseases
  serum ferritin, 315
Alpha$_1$ antitrypsin
  deficiency, aortic aneurysm, 587
  PiZ allele, Wegener's granulomatosis, 543
ANCA-positive vasculitis, 543
Angina
  and sleep in elderly people, 65
Angiotensin-converting enzyme
  pulmonary sarcoidosis, 285
Anthropometric assessment
  coeliac disease, 183
Anti-alpha$_1$-antitrypsin
  and gemfibrozil, 357
Anticoagulation
  control in venous thromboembolism, 143
  haemorrhage, 143, 299
Antihypertensive therapy
  long-term, 37
Antipyrine clearance, 209
Aortic aneurysm
  alpha$_1$ antitrypsin deficiency, 587
Aphthous stomatitis, recurrent
  sucralfate, 341
Arrhythmias
  and sleep in elderly people, 65
Arterial occlusive diseases
  homocyst(e)ine, 603
Aspirin
  haemorrhage, complications, 299
Atherosclerosis
  CHD and peripheral arterial disease, 367
  femoral and carotid arteries, 79
  gemfibrozil, 377
Atherosclerosis, ultrasound
  clinical trials, 575
  hypercholesterolaemia, 561
  intima–media thickness and lumen diameter, 555, 567
  quality control, 581
Atrial natriuretic peptide
  essential hypertension, 665
Autoimmune hepatitis, 31
Autoimmune syndrome type III, 661

Beta adrenergic agonists
  blood pressure in normotensive vs hypertensive subjects, 85
  magnesium in nutrition of hypertensive patients, 189
Biomedical innovation
  duodenal ulcer disease, 501
Biopsy, transbronchial, 461
Birth weight
  and insulin, 275
Blood donors
  hepatitis C, comparisons with other groups, 73
Blood pressure
  direct vs. indirect, 85
  normotensive vs hypertensive, 85
  physical fitness in adolescents, 323
  risk factors, 79
Bone mineral density (BMD), calcium intake, 385

C-peptides
  changes in diabetic patients, 263
Calcium channel blockers
  felodipine effects, 51
  long-term therapy of hypertension, 37
Calcium intake
  ^{42}Ca, effects of insulin, 197
Cardiac diseases
  pheochromocytoma, 93
  sleep in elderly people, 65
Cardiovascular disease
  factitious disorder, 685
  homocyst(e)inaemia, 633
  long-term follow-up, 651
Carotid arteries
  atherosclerosis, 79
Catecholamines
  blood pressure in normotensive vs hypertensive subjects, 85
Chest X-ray
  pulmonary sarcoidosis, 285
  pulmonary tuberculosis, 137
Cholestatic hepatitis
  pacing threshold, 353
Cholesterol, serum
  in cardiovascular disease, 651
  gemfibrozil, 377
  Melanesian population, 331
  risk factors, 79
  wheat fibre effects, 477
Cirrhosis
  protein diets and, 101
Coeliac disease
  malignant lymphoma, 43
  and sarcoidosis, 661
  subclinical, anthropometric assessment, 183
Colorectal carcinoma
  and testicular cancer, 85
Coronary heart disease
  diabetes mellitus (NIDDM), 291
  exercise training, 7, 537
  femoral atherosclerosis in hyperchosterolaemia, 367
  prevention, in Ghana, 251
  prevention and treatment, 111

risk factors, 7, 111
Melanesia, 331
Corticosteroids
giant-cell arteritis, 345
Cryoglobulinaemia, mixed
hepatitis C, 31
Cytokines
acute non-lymphoblastic leukaemia, 487

Deep vein thrombosis
latex D-dimer tests, 691, 692
Diabetes mellitus
fractures in osteoporosis, 203
joint mobility, 215
polyglandular autoimmune syndrome type III, 661
therapies in a total population, 255
Diabetes mellitus (NIDDM)
cardiovascular disease, 651
felodipine effects, 51
hyperandrogenicity as prediabetic condition, 101
islet cell antibodies, 263
metabolic evolution, 263
myocardial infarction, 291
oxide-reductive balance, 495
sulfonylurea therapy, 51, 305
therapy-resistant arterial hypertension, 643
Duodenal ulcer disease
biomedical innovation, 501

Elderly people
sleep, and cardiac diseases, 65
Enteropathy-associated T-cell lymphoma (EATCL), 43
Eosinophilia
strongyloidiasis, 473
Epidemiology
pheochromocytoma in Galicia, Spain, 675
Epstein–Barr virus
familial malignant RA, 469
Erythrocytes
^{42}Ca uptake, effects of insulin, 197
Exercise testing
myocardial infarction, 537
Exercise training
coronary heart disease, 7
see also Physical fitness

Factitious disorder
cardiovascular disease, 685
Felodipine
effects, diabetes mellitus (NIDDM), 51
Femoral arteries
atherosclerosis, 79
Ferritin, serum
transferrin saturation, 315
Fetal development
insulin responses to glucose, 275
Fibre, wheat, 477
Fibrinolysis (minisymposium)
pathophysiology, 411, 425
Folate
plasma level determinants, 633
Fractures in osteoporosis
diabetic complications, 203
transgenic animals, 455

Gallium scintigraphy
pulmonary sarcoidosis, 285
Gastric adenocarcinoma
systemic polyarteritis nodosa, 679
Gastric damage
NSAIDs in rheumatoid arthritis, 153
Gemfibrozil
and anti-alpha$_1$-antitrypsin, 357
in hyperlipidaemia, 377
Genes, expanding, 1
Giant-cell arteritis
female genital tract, 345
Glomerular disease progression, 241
Glucocorticoids
extra-pancreatic tumour hypoglycaemia, 693
Glucose control
long-term therapy of hypertension, 37
Granulocyte–macrophage colony-stimulating factor
acute non-lymphoblastic leukaemia, 487
Grave's disease
radioiodine therapy, 507
Growth factors
fetal development, 275

Haemachromatosis
transferrin saturation, 315
Haematological therapy
pure red cell aplasia of pregnancy, 593
Haemoglobin A1c
diabetes mellitus (NIDDM), 51
Haemorrhage
anticoagulation, 143, 299
warfarin and aspirin, 299
Haemostatic factors
diabetes mellitus (NIDDM), 495
Helicobacter pylori
adoption of medical technology, 501
Hepatitis C virus
autoimmune hepatitis, 31
heterosexual transmission, 515
homosexual men, comparisons with other groups, 73
Hepatitis, cholestatic
pacing threshold, 353
HIV infection
fever of unknown origin, 529
and HCV transmission, 515
HLA-DR4
familial malignant RA, 469
Hodgkin's disease
and testicular cancer, 85
Homocyst(e)inaemia
arterial occlusive diseases, 603
plasma level determinants, 633
Homosexual men
hepatitis C, comparisons with other groups, 73
Hyperandrogenicity, 101
Hyperlipidaemia
gemfibrozil, 377
Hypertension
atrial natriuretic peptide infusion, response, 665
factitious disorder, 685
long-term therapy, 37
magnesium in nutrition, 189
multiple risk factor intervention, 651

porphyria and renal disease, 169
Testicular cancer normotensive vs hypertensive subjects, 85
therapy-resistant, 643
Hyperthyroidism, 507
Hypertriglyceridaemia
long-term therapy of hypertension, 37
serum triglycerides, distribution, 57
Hypoglycaemia
extra-pancreatic tumour, 693
IGF-II-induced, 97
Hypogonadism
and hypodontia, 349
Hypothyroidism, 507
upper airway obstruction, 177

Immunodeficiency syndrome
lactic acidosis, 478
Immunoglobulins
pure red cell aplasia of pregnancy, 593
Immunosuppressive therapy
eosinophilia in strongyloidiasis, 473
paraneoplastic syndrome, 225
Insulin
effects on ^{42}Ca uptake, 197
height and birth weight, 275
resistance, risk factor in CHD, 305
risk factor in CHD, 7
sensitivity, steroid hormones, 521
see also Diabetes mellitus
Insulin-like growth factor-II, 693
tumour-induced hypoglycaemia, 97
Insulin
resistance, risk factor in CHD, 305
Iodine-131
Grave's disease, 507
Irritable bowel syndrome, 23
Isradipine
metabolic effects, 37

Joint mobility
diabetes mellitus (IDDM), 215

Kidney
atrial natriuretic peptide infusion and response, 665

Lactic acidosis
AIDS, 478
Latex D-dimer tests, 691, 692
Left ventricular function
myocardial infarction in NIDDM, 291
Leukaemia, acute myeloid
cost effectiveness, 401
Leukaemia, acute non-lymphoblastic
granulocyte–macrophage colony-stimulating factor, 487
Lipid levels
long-term therapy of hypertension, 37
screening, 115
Lipoproteins
apoA-1, hypertriglyceridaemia, 57
CHD prevention in Ghana, 251
NIDDM patients, 305
risk factors in CHD, 7, 305
Liver diseases
transferrin saturation, 315
Liver function
in patients with osteosarcoma, 209
trimethoprim, 281
Lymphoma, malignant
coeliac disease, 43
enteropathy-associated T-cell lymphoma (EATCL), 43

Magnesium
in nutrition of hypertensive patients, 189
Malnutrition and malabsorption
coeliac disease, 183
warfarin resistance, 465
Melanesia
CHD risk factors, 331
Meta-analysis, 3
'Metabolic fitness', 7
Methotrexate
liver function in patients with osteosarcoma, 209
Microalbuminuria
diabetes (NIDDM), 495
Migraine therapy, 237
Mixed cryoglobulinaemia
hepatitis C, 31
Munchausen's syndrome, 685
Mycobacterial infection
HIV-infected patients, 529
Myocardial infarction
exercise testing and thrombolytic therapy, 537
NIDDM patients, 291
thrombolysis in, 439

Naproxen
gastric damage in rheumatoid arthritis, 153
Neoplasm circulating cells
ovarian tumours, 597
NSAIDs in rheumatoid arthritis
gastric damage, 153

Obesity
hypertriglyceridaemia, 57
sleep apnoea, 177
steroid hormones and insulin sensitivity, 521
Octreotide
in acromegaly, sleep apnoea, 231
Osteoporosis
fractures, and diabetic complications, 203
Osteosarcoma
methotrexate, liver function, 209
Ovarian tumours
neoplasm circulating cells, 597
Oxide-reductive balance
diabetes (NIDDM), 495

Pacemaker
pacing threshold, cholestatic hepatitis, 353
Paraneoplastic syndrome
adenocarcinoma, 679
immunosuppressive therapy, 225
Peptic ulcer disease
personality patterns, 271
Peripheral arterial disease
femoral atherosclerosis, 367
Pheochromocytoma
cardiac, 93
in Galicia, Spain, 675

Physical fitness
  and BP, in adolescents, 323
Pindalol
  with isradipine, 37
Pirprofen
  gastric damage in rheumatoid arthritis, 153
Plasminogen activation, 415
Polyarteritis nodosa
  in gastric adenocarcinoma, 679
Polyglandular autoimmune syndrome type III, 661
Porphyria
  and renal disease, hypertension, 169
Pregnancy
  pure red cell aplasia, 593
Professional standards, 363
Propafenone-induced cholestatic hepatitis, 353
Protein diets
  cirrhosis, 101
  vegetable vs animal origins, 101, 102
Proteinase-3, 543
Prothrombin time
  warfarin effects, 465
Pulmonary function tests
  sarcoidosis, 285
Pulmonary hypertension
  neoplasm circulating cells, 597
Pulmonary lymphangioleiomyomatosis, 461
Pulmonary occlusive disease, 603
Pure red cell aplasia
  pregnancy, 593

Radioiodine therapy
  Grave's disease, 507
Renal disease
  hypertension, and porphyria, 169
Rheumatoid arthritis
  malignant, familial, 469
  NSAIDs, gastric damage, 153
Rheumatoid synovitis
  radiosynovectomy, 479

Sarcoidosis
  and coeliac disease, 661
  pulmonary function tests, 285
Sexual transmission of disease, 515
Single photon absorptiometry
  bone mineral density (BMD), 385
SLE nephritis
  hypertension, and porphyria, 169
Sleep apnoea
  in hypothyroidism, 177
  octreotide in acromegaly, 231
Sleep in elderly people
  cardiac diseases, 65
Smoking
  and atherosclerosis, 79
  hypertriglyceridaemia, 57
Spain
  incidence of pheochromocytoma, 675
Steroid hormones
  and insulin sensitivity, 521
Stroke
  assessment system, 125
Strongyloidiasis
  eosinophilia, 473
Sucralfate
  aphthous stomatitis, recurrent, 341
Sulfonamides
  liver function, 281
Sulfonylurea
  NIDDM, felodipine effects, 51
  NIDDM, vs. insulin, 305
  therapies in a total population, 255

T-cell-mediated immunity
  paraneoplastic syndrome, 225
Temporal arteritis
  corticosteroids, 345
Testicular cancer
  and colorectal carcinoma, 85
Therapy resistance
  arterial hypertension, 643
Thrombolytic agents
  AMI, 439
  noncardiac disorders, 447
  novel, 433
Thrombolytic therapy
  AMI, exercise testing, 537
Thrombosis
  fibrinolytic system, 411
  latex D-dimer tests, 691, 692
Transferrin
  saturation, liver diseases, 315
Triglycerides *see* Hypertriglyceridaemia
Trimethoprim
  liver function, 281
Tuberculosis
  diagnosis delay, 137
Tumour-induced hypoglycaemia
  IGF-II levels, 97

Upper airway obstruction
  hypothyroidism, 177

Valsava manoeuvre
  factitious disorder, 685
Vasculitic neuropathy
  paraneoplastic syndrome, 225
Vasculitis
  ANCA-positive, 543
  HLA-DR4, 469
Venous thromboembolism
  anticoagulant control, 143
Visceral fat
  insulin sensitivity, 521
Vitamin B_{12}
  plasma level determinants, 633

Warfarin
  bleeding complications, 299
  resistance due to malabsorption, 465
Wegener's granulomatosis
  alpha$_1$ antitrypsin PiZ allele, 543
Wolff–Parkinson–White syndrome
  hypogonadism, 349